Singapore, May 16, 2025 — Basel Medical Group Ltd (Nasdaq: BMGL or the “Company”) announced today that it has entered exclusive negotiations for a US$1 billion Bitcoin (BTC) acquisition. This move aims to significantly diversify its treasury reserves while maintaining its primary focus on expanding medical services. This major strategic financial initiative is designed to strengthen the company’s balance sheet and support its ambitious expansion plans in Asia’s rapidly growing healthcare markets.

Strategic Financial Restructuring for Growth

BMGL is in advanced discussions with a consortium of institutional investors and high-net-worth individuals prominent in the crypto space to acquire US$1 billion in BTC through an innovative share-swap agreement. Management believes that this significant transaction, if successful, will be one of the largest enhancements to a corporate balance sheet in the Asia-Pacific healthcare sector.

Strengthening the Foundation for Regional Expansion

The proposed US$1 billion capital infusion will:

• Establish one of the strongest balance sheets among healthcare providers focused on Asia;
• Provide considerable financial flexibility for mergers and acquisitions;
• Create a diversified asset base to mitigate market volatility; and
• Position BMGL as a well-funded medical group in emerging Asian markets.

Dr. Darren Chhoa, CEO of BMGL, stated, “This US$1 billion financial transformation will provide us with unparalleled capacity to implement our Asia growth strategy while maintaining prudent financial management. Our strengthened balance sheet will enable us to capitalize on strategic opportunities as we develop a leading healthcare platform across high-growth Asian markets.”

The Company anticipates finalizing the terms this quarter, pending standard closing conditions and regulatory approvals.

About Basel Medical Group Ltd

Basel Medical, based in Singapore, offers orthopedic and trauma services, sports medicine and surgery, orthopedic procedures, and neurosurgical treatments. Our clinics are located at 6 Napier Road, Unit #02-10/11 and Unit #03-07, Gleneagles Medical Centre, Singapore. Over the past 20 years, we have built strong, enduring relationships with a broad base of corporations, particularly in the construction, marine, and oil & gas industries, which support our robust business model. As a long-standing orthopedic service provider in Singapore with over 20 years of experience, we are well-positioned to leverage the growth opportunities in Singapore’s and Southeast Asia’s private healthcare industry. These opportunities are driven by aging populations, rising income levels, increased private insurance coverage, government healthcare initiatives and spending, growing sports participation, and Singapore’s standing as a premier healthcare destination in Asia. Our management and medical practitioner team includes orthopedic and neurosurgery specialists, as well as corporate finance and healthcare partnership specialists. Basel Medical Group Ltd, the holding company of our group, conducts operations through its Singapore-based operating subsidiaries. For more information, please visit www.baselmedical.com.

Forward-Looking Statements

This announcement contains forward-looking statements involving known and unknown risks and uncertainties, based on the Company’s current expectations and projections regarding future events that may impact its financial condition, operating results, business strategy, and financial needs. These statements can often be identified by the use of terms such as “aim,” “anticipate,” “believe,” “estimate,” “expect,” “going forward,” “intend,” “may,” “plan,” “potential,” “predict,” “propose,” “seek,” “should,” “will,” “would,” or similar expressions. The Company is not obligated to update or revise any forward-looking statements to reflect new events or circumstances, or changes in its expectations, except as legally required. While the Company believes these forward-looking statements are reasonable, it cannot guarantee their accuracy and advises investors that actual results may differ significantly from anticipated results. Investors are encouraged to review other factors that could affect the Company’s future performance in its filings with the SEC.

Media Contact:
Basel Medical Group Ltd
+65 6291 9188